Back to Newsroom

Conatus Pharmaceuticals Announces Acceptance of Emricasan Abstracts for AASLD Annual Meeting

Emricasan Improves Liver Function in Cirrhosis Patients with NASH and/or Elevated MELD Scores

Emricasan Improves Hepatic Blood Flow, Portal Hypertension, and Liver Function in Animal Models

SAN DIEGO, Oct. 03, 2016 (GLOBE NEWSWIRE) — Conatus Pharmaceuticals Inc. (NASDAQ:CNAT) announced today that abstracts for four posters — two addressing clinical results and two addressing preclinical results with the company’s pan-caspase inhibitor, emricasan — have been accepted for presentation at The Liver Meeting®, the annual meeting of the American Association for the Study of Liver Diseases (AASLD) in Boston November 11-15, 2016.


Click here to read the full release